Review
Oncology
Luis Cabezon-Gutierrez, Sara Custodio-Cabello, Magda Palka-Kotlowska, David Diaz-Perez, Maria Mateos-Dominguez, Pablo Galindo-Jara
Summary: This review summarizes the evidence from studies on the efficacy and tolerability of neoadjuvant immunotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) Locally Advanced Rectal Cancer (LARC). A total of 92 studies were obtained, but only 9 were included in the final analysis, showing overall response rates of 100%. The promising results suggest the potential to explore alternative treatments for these patients in the future.
Review
Oncology
Tugba Akin Telli, Giacomo Bregni, Michele Vanhooren, Rita Saude Conde, Alain Hendlisz, Francesco Sclafani
Summary: Immune checkpoint inhibitors (ICIs) have shown remarkable efficacy in cancer treatment, but their therapeutic potential in colorectal cancer is limited. Previous studies have focused on strategies to overcome resistance to ICIs, and the combination of ICIs with multi-kinase inhibitors is being widely investigated. Multi-kinase inhibitors can synergistically enhance the recognition and targeting of cancer cells by the immune system.
CANCER TREATMENT REVIEWS
(2022)
Article
Oncology
Akinao Kaneta, Shotaro Nakajima, Hirokazu Okayama, Takuro Matsumoto, Katsuharu Saito, Tomohiro Kikuchi, Eisei Endo, Misato Ito, Kosaku Mimura, Yasuyuki Kanke, Motonobu Saito, Zenichiro Saze, Shotaro Fujita, Wataru Sakamoto, Hisashi Onozawa, Tomoyuki Momma, Shinji Ohki, Koji Kono
Summary: This study found that the activation of the cGAS-STING pathway contributes to the recruitment of CD8(+) TILs in dMMR/MSI CRC.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Gastroenterology & Hepatology
Richarda M. de Voer, Illja J. Diets, Rachel S. van der Post, Robbert D. A. Weren, Eveline J. Kamping, Tessa J. J. de Bitter, Lisa Elze, Rob H. A. Verhoeven, Elisa Vink-Borger, Astrid Eijkelenboom, Arjen Mensenkamp, Iris D. Nagtegaal, Marjolijn C. J. Jongmans, Marjolijn J. L. Ligtenberg
Summary: This study analyzed clinical, molecular, and genetic features of colorectal cancers in adolescents and young adults, finding that 39% of patients had a genetic tumor risk syndrome. The study highlights differences in CRC characteristics between young patients and older patients, suggesting the need for new clinical management strategies.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Oncology
Natalya Risinskaya, Yana Mangasarova, Elena Nikulina, Yana Kozhevnikova, Julia Chabaeva, Anna Yushkova, Aminat Magomedova, Sergey Kulikov, Hunan Julhakyan, Sergey Kravchenko, Andrey Sudarikov
Summary: This study assessed the incidence of LOH, EMAST, and MSI in PMBCL patients and found no associations with the clinical outcome.
Article
Oncology
Ana Oaknin, Anna Tinker, Lucy Gilbert, Vanessa Samouelian, Cara Mathews, Jubilee Brown, Maria-Pilar Barretina-Ginesta, Victor Moreno, Adriano Gravina, Cyril Abdeddaim, Susana Banerjee, Wei Guo, Hadi Danaee, Ellie Im, Renaud Sabatier
Summary: This document summarizes the GARNET trial, which focused on treating patients with dMMR endometrial cancer with dostarlimab and showed efficacy in shrinking tumors in some patients. The percentage of participants experiencing side effects was low and within expectations for this type of treatment.
Review
Oncology
Laura Matteucci, Alessandro Bittoni, Graziana Gallo, Laura Ridolfi, Alessandro Passardi
Summary: The majority of metastatic colorectal cancer cases are resistant to Immune Checkpoint Inhibitors, but there are strategies to overcome this resistance and expand the use of immunotherapy, including combination with chemotherapy and targeted drugs, sequential treatment with specific drugs, and validation of immunohistochemical biomarkers.
Article
Oncology
Quang Loc Bui, Leo Mas, Antoine Hollebecque, David Tougeron, Christelle de la Fouchardiere, Thomas Pudlarz, Emily Alouani, Rosine Guimbaud, Julien Taieb, Thierry Andre, Raphael Colle, Romain Cohen
Summary: This study retrospectively collected clinical data from 31 patients with dMMR/MSI mCRC. The results showed that there was no improved outcome with CT after ICI failure, but prolonged disease control was observed in some cases.
Review
Immunology
Xuan Zhang, Tao Wu, Xinyi Cai, Jianhua Dong, Cuifeng Xia, Yongchun Zhou, Rong Ding, Renfang Yang, Jing Tan, Lijuan Zhang, Ya Zhang, Yuqin Wang, Chao Dong, Yunfeng Li
Summary: Patients with locally advanced colorectal cancer and high microsatellite instability/deficient mismatch repair (MSI-H/dMMR) receive little benefit from neoadjuvant therapy. However, immunotherapy with immune checkpoint inhibitors may change the treatment approach and have implications for neoadjuvant therapy in other cancers.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Camilla Di Dio, Giorgio Bogani, Violante Di Donato, Ilaria Cuccu, Ludovico Muzii, Lucia Musacchio, Giovanni Scambia, Domenica Lorusso
Summary: Endometrial cancer is a heterogeneous disease with specific genomic, molecular, and biological features. Immune checkpoint inhibitors and tyrosine kinase inhibitors have shown promising results in the treatment of advanced or recurrent endometrial cancer. The combination of pembrolizumab and lenvatinib has become the new standard second-line treatment, regardless of the MMR status. Further studies are exploring the use of immune checkpoint inhibitors and PARP inhibitors in combination therapy.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Namkee Oh, Hyunki Kim, Kyoung-Mee Kim, Jae-Ho Cheong, Jeeyun Lee, Sung Hoon Noh, Tae Sung Sohn, Yoon Young Choi, Ji Yeong An
Summary: Microsatellite status may not be a prognostic factor for tumor recurrence or a predictor of response to adjuvant treatment in pT1N1 gastric cancer patients. Considering that the effect of adjuvant treatment to decrease the risk of tumor recurrence is not clear, it may not be indicated in pT1N1 patients.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Oncology
Hui Wu, Wenyuan Ma, Congfa Jiang, Ning Li, Xin Xu, Yongfeng Ding, Haiping Jiang
Summary: Gastric cancer is a common and fatal malignant tumor. Microsatellite instability (MSI) has become a major molecular typing approach for gastric cancer, especially in advanced cases. However, its value in resectable gastric cancer is still unclear, and there is no consensus on postoperative adjuvant therapy for MSI-H/dMMR resectable GC patients.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Oncology
Julie Leclerc, Catherine Vermaut, Marie-Pierre Buisine
Summary: Microsatellite instability (MSI) is a hallmark of Lynch syndrome (LS)-related tumors, but it is not exclusive to LS, as most MSI/mismatch repair-deficient (dMMR) tumors are sporadic. Advances in diagnostic and screening strategies have evolved in recent years, focusing on identifying LS patients and distinguishing LS-related from sporadic MSI tumors. Discussions on pitfalls associated with current strategies aim to improve LS diagnosis and prevent inappropriate clinical management.
Review
Genetics & Heredity
Kristina Vukovic Derfi, Anamarija Salar, Tamara Cacev, Sanja Kapitanovic
Summary: Microsatellite instability (MSI) is the accumulation of frameshifts in short tandem repeats, microsatellites, due to defective DNA mismatch repair (dMMR). Recently, another type of microsatellite instability called elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) has been reported across various tumors. The clinical significance of EMAST and its relation to MSI remains unclear.
Article
Oncology
Valentina Tuninetti, Luca Pace, Eleonora Ghisoni, Virginia Quara, Francesca Arezzo, Andrea Palicelli, Vincenzo Dario Mandato, Elena Geuna, Gennaro Cormio, Nicoletta Biglia, Lucia Borsotti, Silvia Gallo, Annamaria Ferrero, Elena Jacomuzzi, Luca Fuso, Jeremy Oscar Smith Pezua Sanjinez, Andrea Puppo, Andrea Caglio, Chiara Rognone, Margherita Turinetto, Giulia Scotto, Massimo Di Maio, Giorgio Valabrega
Summary: Endometrial cancer (EC) is the most common gynecological malignancy, and there has been an increase in incidence and disease-related mortality in recent years. Limited data is available on the response to first-line carboplatin plus paclitaxel in EC. The retrospective RAME study aimed to assess chemotherapy response in MSI-h/dMMR and MSI-l/pMMR EC patients, and found that patients with MSI-l/pMMR had numerically longer PFS and OS compared to MSI-h/dMMR patients in the first-line setting.
Article
Oncology
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourley, Amit Oza, Antonio Gonzalez-Martin, Carol Aghajanian, William Bradley, Cara Mathews, Joyce Liu, John McNamara, Elizabeth S. Lowe, Mei-Lin Ah-See, Kathleen N. Moore
Summary: Maintenance therapy with olaparib showed sustained progression-free survival benefit in newly diagnosed advanced ovarian cancer patients with a BRCA mutation. After a 7-year follow-up, there was a clinically meaningful improvement in overall survival. The incidence of myelodysplastic syndrome and acute myeloid leukemia was low.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jacques-Olivier Bay, Carole Bouleuc, Christophe Caux, Frederic Delom, Nelly Firmin, Virginie Gandemer, Gilles L'Allemain, Nicolas Magne, Daniel Orbach, Jacques Robert, Manuel Rodrigues, Renaud Sabatier, Antoine Thiery-Vuillemin, Marie Wislez
Summary: This article presents the analysis of highlights from 2022 by the editorial committee members of The Cancer Bulletin. Their objective is to provide readers with a thoughtful, educational, and practical reading by analyzing published data and placing it in the context of cancer management. The goal is to offer rational bases for different treatment approaches in 2023.
BULLETIN DU CANCER
(2023)
Article
Oncology
Alessandro D. Santin, Ignace Vergote, Antonio Gonzalez-Martin, Kathleen Moore, Ana Oaknin, Ignacio Romero, Sami Diab, Larry J. Copeland, Bradley J. Monk, Robert L. Coleman, Thomas J. Herzog, Jonathan Siegel, Linda Kasten, Andreas Schlicker, Anke Schulz, Karl Kochert, Annette O. Walter, Barrett H. Childs, Cem Elbi, Iurie Bulat
Summary: This study aimed to determine the safety, pharmacokinetics, and anti-tumor activity of anetumab ravtansine and pegylated liposomal doxorubicin in mesothelin-expressing platinum-resistant ovarian cancer. The results showed that this combination therapy demonstrated tolerability and promising clinical activity. Rating: 9/10.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Flora Brouillard-Saby, Caroline Saint-Martin, Isabelle Ray-Coquard, Laurence Gladieff, Christophe Pomel, Pierre-Emmanuel Colombo, Jean-Marc Classe, Marion Chevrier, Florence Joly, Thibault De la Motte Rouge, Anne Floquet, Renaud Sabatier, Emmanuel Barranger, Helene Costaz, Eric Leblanc, Frederic Marchal, Patricia Pautier, Lise Bosquet, Manuel Rodrigues
Summary: Chemotherapy options for platinum-sensitive relapse of high-grade serous ovarian cancers include carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin. BRCA mutated patients are sensitive to replicative stress agents, but BRCA status is not currently used for chemotherapy selection. This study aimed to assess the effectiveness of these doublets according to BRCA status in first platinum-sensitive relapse.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Ursula A. A. Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Andrew Dean, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason A. A. Konner, Margarita Romeo Marin, Philipp Harter, Conleth G. G. Murphy, Jiuzhou Wang, Elizabeth Noble, Brooke Esteves, Michael Method, Robert L. L. Coleman
Summary: The MIRV antibody-drug conjugate demonstrated significant antitumor activity and favorable tolerability in patients with platinum-resistant epithelial ovarian cancer, particularly in those who had received multiple prior therapies including bevacizumab.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Gwenaelle Gravis, Patricia Marino, Daniel Olive, Frederique Penault-LLorca, Jean-Pierre Delord, Clotilde Simon, Assia Lamrani-Ghaouti, Renaud Sabatier, Joseph Ciccolini, Jean-Marie Boher
Summary: The study aims to investigate whether reducing the dose and frequency of immunotherapy after 6 months of standard treatment can maintain the efficacy for metastatic cancer. A total of 646 patients will be recruited and randomly assigned into two groups, standard immunotherapy group and reduced intensity group, to compare their efficacy, survival rate, and toxicity. This study could provide insights into a more cost-effective, less toxic, and improved quality of life treatment approach.
Article
Oncology
Renaud Sabatier, Frederique Rousseau, Florence Joly, Claire Cropet, Coline Montegut, Johanna Frindte, Saverio Cinieri, Eva M. Guerra Alia, Stephan Polterauer, Hiroyuki Yoshida, Ignace Vergote, Nicoletta Colombo, Sakari Hietanen, Remi Largillier, Ulrich Canzler, Alain Gratet, Frederik Marme, Laure Favier, Eric Pujade-Lauraine, Isabelle Ray-Coquard
Summary: In the PAOLA-1 study, maintenance olaparib plus bevacizumab was found to improve progression-free survival in older patients with advanced ovarian cancer, with similar efficacy and safety to younger patients.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Juan-Francisco Grau, Lorena Farinas-Madrid, Carmen Garcia-Duran, David Garcia-Illescas, Ana Oaknin
Summary: Cervical cancer is a major public health problem, ranking fourth in terms of incidence and mortality among women globally. Immune checkpoint inhibitors have dramatically improved the treatment of this disease, leading to historical overall survival improvements. However, the efficacy of immunotherapy in locally advanced cervical cancer is still disappointing, although promising data are emerging from early-phase trials of novel immunotherapy approaches. This review summarizes the main clinical trials conducted in the field of immunotherapy in recent years.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Jose Alejandro Perez-Fidalgo, Eva Guerra, Yolanda Garcia, Maria Iglesias, Maria Hernandez-Sosa, Purificacion Estevez-Garcia, Luis Manso Sanchez, Ana Santaballa, Ana Oaknin, Andres Redondo, M. Jesus Rubio, Antonio Gonzalez-Martin
Summary: This study aimed to determine the potential prognostic value of clinical and molecular biomarkers in the survival of platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin. The study found that a high neutrophil/lymphocyte ratio was associated with worse overall survival in patients at platinum-resistant relapse treated with olaparib and pegylated liposomal doxorubicin.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
David Cibula, Maria Rosaria Raspollini, Francois Planchamp, Carlos Centeno, Cyrus Chargari, Ana Felix, Daniela Fischerova, Daniela Jahnn-Kuch, Florence Joly, Christhardt Kohler, Sigurd Lax, Domenica Lorusso, Umesh Mahantshetty, Patrice Mathevet, Raj Naik, Remi A. Nout, Ana Oaknin, Fedro Peccatori, Jan Persson, Denis Querleu, Sandra Rubio Bernabe, Maximilian P. Schmid, Artem Stepanyan, Valentyn Svintsitskyi, Karl Tamussino, Ignacio Zapardiel, Jacob Lindegaard
Summary: In 2018, ESGO, ESTRO, and ESP jointly published evidence-based guidelines for the management of patients with cervical cancer. The update includes new topics to provide comprehensive guidelines on all relevant issues of diagnosis and treatment.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Medicine, Research & Experimental
Elsa Nigon, Claudia Lefeuvre-Plesse, Alejandra Martinez, Celine Chauleur, Alain Lortholary, Laure Favier, Anne-Sophie Bats, Arnaud Guille, Jose Adelaide, Pascal Finetti, Victoire de Casteljac, Magali Provansal, Emilie Mamessier, Francois Bertucci, Isabelle Ray-Coquard, Renaud Sabatier
Summary: This multicenter retrospective study aimed to explore the clinical and molecular features of uterine clear cell carcinomas. The study found that most patients with uterine CCC were diagnosed at an early stage and received surgery, radiation, and chemotherapy as treatments. Some patients showed immune response-associated features and had a better prognosis.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Manuel Rodrigues, Lauriane Eberst, Philippe Follana, Ludiane Gauthier, Virginie Jacquemin, Christophe Tessier, Nadia El Mouaddin, Philippe Boudier, Frederic Fiteni, Eurydice Angeli, Sophie Roche, Nicolas Delanoy, Renaud Sabatier, Ronan Flippot, Thibault de la Motte Rouge
Summary: This study conducted a descriptive analysis of patients granted temporary authorization to use dostarlimab, finding that the treatment response rate and disease control rate were consistent with clinical trial results. The study highlights the need for novel treatment options for patients in France who have undergone platinum-based therapy.
BULLETIN DU CANCER
(2023)
Editorial Material
Oncology
Ana Oaknin, Lucy Gilbert, Anna Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M. O'Malley, Vanessa Samouelian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeleit, Charles Leath III, Yuping Dong, Jennifer Veneris, Bhavana Pothuri
Summary: This summary is about a drug called Dostarlimab, which is used to treat certain types of endometrial cancer. The GARNET study is testing the safety and administration of Dostarlimab, and the results showed its effectiveness in reducing tumor size with manageable side effects.
Article
Oncology
Nicoletta Colombo, Toon Van Gorp, Ursula A. Matulonis, Ana Oaknin, Rachel N. Grisham, Gini F. Fleming, Alexander B. Olawaiye, Dorothy D. Nguyen, Andrew E. Greenstein, Joseph M. Custodio, Hristina I. Pashova, Iulia C. Tudor, Domenica Lorusso
Summary: This study aimed to investigate the therapeutic effect of selective glucocorticoid receptor modulation with relacorilant in platinum-resistant/refractory ovarian cancer. The results showed that intermittent relacorilant plus nab-paclitaxel significantly improved progression-free survival, duration of response, and overall survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, Lisa Belin, Katharina Leitner, David Cibula, Hannelore Denys, Ora Rosengarten, Manuel Rodrigues, Nikolaus de Gregorio, Jeronimo Martinez Garcia, Edgar Petru, Roman Kocian, Ignace Vergote, Patricia Pautier, Barbara Schmalfeldt, Lydia Gaba, Stephan Polterauer, Marie-Ange Mouret Reynier, Jalid Sehouli, Cristina Churruca, Frederic Selle, Florence Joly, Veronique D'Hondt, Emilie Bultot-Boissier, Coriolan Lebreton, Jean-Pierre Lotz, Remy Largillier, Pierre-Etienne Heudel, Florian Heitz
Summary: In patients with recurrent ovarian cancer after a platinum-free interval of more than 6 months, the combination of platinum-based doublets with bevacizumab and chemotherapy did not significantly improve progression-free survival. Immunotherapy holds potential for late-relapsing ovarian cancer and further research is needed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)